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BACKGROUND: Sessile serrated adenomas/polyps (SSA/P) are now recognised precursors of colorectal cancer
(CRC) including cancers harbouring somatic BRAF (V600E) mutations. While the morphological diagnostic criteria
of SSA/P have been established, distinguishing between small/early SSA/P and microvesicular hyperplastic polyps
(MVHP) is challenging and may not be possible in routine practice.METHODS: Gene expression profiling of MVHP
(n=5, all BRAF V600E wild-type) and SSA/P (n=5, all BRAF V600E mutant) samples was performed. Quantitative
reverse transcription–polymerase chain reaction (qRT-PCR) and immunohistochemical analysis was performed to
verify the expression of claudin 1 (CLDN1) in MVHP and SSA/P. RESULTS: Gene expression profiling studies
conducted between MVHP and SSA/P identified CLDN1 as the most statistically significant differentially expressed
gene (pb0.05). Validation with qRT-PCR confirmed an up-regulation of CLDN1 in BRAF V600E mutant polyps
regardless of polyp type (pb0.0005). Immunohistochemical analysis of CLDN1 expression in BRAF V600E mutant
SSA/Ps (n=53) and MVHPs (n=111) and BRAF wild-type MVHPs (n=58), demonstrated a strong correlation
between CLDN1 expression and the BRAF V600E mutation in both SSA/P and MVHP samples when compared to
wild-type polyps (pb0.0001). CONCLUSION: This study demonstrates an up regulation of CLDN1 protein in
serrated colorectal polyps including MVHP harbouring the BRAF V600E mutation. Our results demonstrated an
apparent heterogeneity on the molecular level within the MVHP group and suggest that MVHP with somatic BRAF
V600E mutation and up-regulated expression of CLDN1 are closely related to SSA/P and may in fact represent a
continuous spectrum of the same neoplastic process within the serrated pathway of colorectal carcinogenesis.
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While the majority of colorectal cancer (CRC) is believed to evolve
through the conventional adenoma to carcinoma sequence, initially
proposed byVogelstein [1], it has become apparent that asmany as 30%
of CRCs may arise through an alternate route, known as the serrated
pathway [2]. The sessile serrated adenoma/polyp (SSA/P) has been
recently accepted as the most common precursor lesion for this pathway
and its correct identification in clinical and pathologic practice is of
critical importance. Currently, pathologic diagnosis of SSA/P is based
on a constellation of cytoarchitectural histopathologic features including
the degree of crypt dilation and serration, the horizontal crypt
configuration, number of branched crypts and nuclear features [3,4].
However, SSA/Ps, particularly when small, have overlapping micro-
scopic features with other serrated polyps, including microvesicular
hyperplastic polyps (MVHP), and distinction between these lesions
may not always be possible in routine pathology practice. On a
molecular level, the serrated pathway is characterized by the V600E
somatic mutation in the BRAF proto-oncogene (BRAF V600E),
cytosine guanine dinucleotide island methylator phenotype (CIMP),
and microsatellite instability (MSI) [4,5]. The BRAF V600E mutation
is hypothesized to be an early event in this pathway that potentially
drives tumorigenesis [5], whereas in the conventional pathway,
mutations in the adenomatous polyposis coli gene and aberrant Wnt
signaling are widely accepted as initiating events [6].
Despite the growing data on molecular features of the serrated
pathway, our understanding of the key biologic events involved in the
development of polyps in this pathway and their progression to
carcinoma is still not complete. Molecular studies including gene
expression profiling comparing different subsets of CRC precursor
lesions have advanced our knowledge on themolecular events occurring
during the neoplastic progression in these lesions, providing additional
support for distinct molecular pathways involved in tumorigenesis of
this subset of CRC [7–10]. Recent gene expression analysis of serrated
and conventional colorectal carcinomas has also suggested that CRCs
developing through the serrated pathway may require different
chemotherapy treatment regimes [11–13]. This is further supported
by recent studies that demonstrated colorectal adenocarcinomas
characterized by the BRAF V600E mutation have significantly worse
overall survival when compared to BRAF wild-type or KRAS mutated
adenocarcinomas [3,14–16]. Additionally, SSA/Ps have been reported
to be of higher risk of progression [17,18].
Our study attempted the further investigation of underlying
molecular alterations in serrated colorectal polyps through gene
expression profiling. In validation studies, we employed quantitative
reverse transcription–polymerase chain reaction (qRT-PCR) and
routine immunohistochemical techniques available in most pathology
laboratories using samples from surgical resections and polypectomies.
We have identified claudin-1 (CLDN1) as significantly upregulated in
polyps bearing the BRAF V600E somatic mutation both on a gene
expression level and a protein level, regardless of polyp type. Our results
indicate that CLDN1 up-regulation occurs early in the development of
SSA/P and its overexpression in a proportion of MVHP suggests a close
relation between these two lesions of the serrated pathway.Materials and Methods
Patients and Polyp Samples
Polyp samples used inmicroarray gene expression profiling and qRT-
PCR were obtained from surgical resection specimens. The freshresection specimens were examined and sampled in a hospital
immediately after resection or in the pathology laboratory within
30 minutes of resection. Each polyp was divided into equal portions.
Portions were either immediately snap-frozen in liquid nitrogen or
formalin fixed and paraffin embedded (FFPE). The frozen sections
selected for the study were further verified histologically before analysis.
The diagnostic criteria for SSA/P and MVHP are based on
published criteria relying mainly on polyp architecture [9]. The
architectural features assessed included crypt branching, horizontal
dilatation of basal crypt compartments, and presence of serration at
the base of the crypts. Polyps were classified as SSA/P when at least
two of these features were present, and only lesions with a sessile
configuration and a diameter of 10 mm or more from the right
colon (up to the splenic flexure) were classified as SSA/P; MVHP
were obtained from the left colon and were b5 mm in diameter.
None of the polyps used in microarray gene profiling or RT-PCR
contained pericryptal stromal spindle cells, had a conventional
adenoma component, or had dysplasia. In addition to morphology,
polyps were also characterized by BRAF and KRAS mutation
analyses. No polyps that carried both the BRAF and KRAS
mutations were identified.
Informed consent was obtained from patients before the use of
their samples, and the study was approved by the Royal Adelaide
Ethics Committee (RAH Protocol No. 001201).
KRAS and BRAF Mutation Screening
DNA was prepared from polyp tissue macro-dissected from FFPE
slides using the QIAamp DNA FFPE Tissue Kit (Qiagen, Valencia,
CA). Screening for mutations in codons 12 and 13 of the KRAS gene
was performed using a multiplex assay as described by Di Fiore et al.
[19]. The V600E mutation in the BRAF gene was detected using a
single nucleotide primer extension assay comparable to the KRAS assay.
The portion of exon 15 of the BRAF gene encompassing the V600E
mutation was amplified, and the V600Emutation was detected using a
SNaPshot Multiplex Kit (Applied Biosystems, Foster City, CA) and a
specific primer (C5TGATTTTGGTCTAGCTACAG). All reactions
were run on a 3730 capillary sequencer (Applied Biosystems),
and results were analyzed using GeneMapper software version 4.0
(Applied Biosystems).
Microarray Analysis
Frozen samples were sectioned at 6 μm using a cryostat (−25°C)
and were immediately stored at −80°C. Before use, the slides were
fixed with ice-cold 100% methanol for 10 minutes and then washed
with Diethylpyrocarbonate-treated water on ice for 30 seconds and
stained with RNase-free hematoxylin solution (Sigma-Aldrich, St
Louis, MO) for 1 minute. Finally, the slides were dehydrated with
100% ethanol for 30 seconds and air-dried.
The stained slides were placed onto a PALM Laser Capture
dissecting microscope (Zeiss, Oberkochen, Germany). The
serrated crypt epithelium of the polyp was catapulted and captured
into 50 μl of lysis/binding buffer (Qiagen) using ultraviolet laser
cutting according to the manufacturer's recommended protocol.
The captured cells were centrifuged, vortexed, and stored at −80°C
until RNA isolation. Total RNA was prepared, including column
DNase digestion, using the QIAGEN RNeasyPlus Mini Kit
(Qiagen). The RNA integrity and concentration for each sample
were assessed using the Agilent BioAnalyzer. Only those samples
with RNA integrity greater than 5 were used for analysis.
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used for gene expression analysis. Extracted RNA from each tissue
sample was amplified, fragmented, and biotinylated before hybrid-
ization to individual arrays. The hybridized arrays were then loaded
onto the Affymetrix Gene Chip Fluidics 450 station, washed, and
then stained with a fluorescently labeled antibody. Arrays were
scanned using a high-resolution scanner (Affymetrix 3000 7G) by the
Adelaide Microarray Centre (Adelaide, Australia).
Statistical Analysis of Microarray Data
Analysis of microarray data was performed using the Partek Genomics
Suite (v 6.6; Partek Inc, St Louis, MO). Raw data files were imported
using robust multichip averaging background correction, quantile
normalization, and median polish probe set summarization. Raw
intensity values were adjusted for base-pair (GC) content and probe-
specific effects. Differential gene expression was assessed by analysis of
variance using the multiple test correction to control for false discovery
rate [20]. Gene expression changes between polyp types were considered
significant when adjusted P values were less than .05. Ingenuity Pathway
Analysis (Ingenuity Systems, Inc, Redwood City, CA) was used to
identify potential relationships between differentially expressed genes.
qRT-PCR of CLDN1
RNA was isolated, and its integrity was assessed as for the microarray
study. In addition, normal colonic mucosa samples (n = 10) obtained
from colorectal resections for non-neoplastic conditions were used for
the preparation of a pooled, normal reference RNA. The samples were
collected, processed, and histologically verified in a similar manner to
the polyp tissues.
RNA (10 ng) was converted to cDNA using the iScript cDNA
Synthesis Kit (Bio-Rad, Hercules, CA) as per the manufacturer’s
instructions using the iQ5 Bio-Rad real-time instrument. Briefly, a 20
μl reaction (containing 5 μl of reaction mixture, 10 ng of RNA, and 5
μl of nuclease-free water) was cycled as follows: 5 minutes at 25°C,
and then 30 minutes at 42°C, 5 minutes at 85°C, cooled to 4°C, and
then again heated to 85°C for 5 minutes.
qRT-PCRs were carried out in triplicate using the iQ SYBRGREEN
Supermix (Bio-Rad) according to the manufacturer’s instructions.
Briefly, a 20 μl reaction (containing 10 μl of iQ SYBR GREEN
Supermix, 200 nM each of forward and reverse primers, 2 μl of cDNA
template, and nuclease-free water) was cycled on the iQ5 Bio-Rad real-
time instrument as follows: 95°C for 3 minutes, then 40 cycles of 95°C
for 15 seconds, 58°C for 30 seconds, and 72°C for 30 seconds.
To avoid amplification of genomic DNA, primers were designed
to span across two exons. Primers were optimized, and a melt curve
analysis was performed to ensure specificity. The cycle threshold
value was used to calculate the normalized expression of the selected
genes for each sample using the software provided with the iQ5 Bio-
Rad real-time instrument. The following primer pairs were used:
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (as a control
gene) forward primer, 5′CAAGGCTGTGGGCAAGGT3′ and
reverse primer, 5′GGAAGGCCATGCCAGTGA3′; CLDN-1 for-
ward primer, 5′CTGCCCCAGTGGAGGATTTA3′ and reverse
primer, 5′GACATCCACAGCCCCTCGTA3′.Immunohistochemical Analysis of CLDN1
Sections (4 μm) of paraffin wax–embedded tissue were mounted
on coated slides, dewaxed, and rehydrated using standard techniques.
Pressure cooker antigen retrieval was performed in 10 mM citratebuffer (pH 6) for 20 minutes. After cooling to 30°C, the sections were
incubated for 60 minutes at room temperature with primary CLDN1
monoclonal antibody (1:2500 dilution; Zytomed Systems GmbH,
Berlin Germany). The polymer system ADVANCE HRP (Dako
Australia Pty Ltd, Victoria, Australia) employing DAB as the detection
system was used. Counterstaining was performed using Mayer’s
hematoxylin. Samples were scored as positive if staining was detected
in any of the polyp crypts and negative if there was no staining present.
A negative control was performed by omitting the primary antibody.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism (v5.0;
GraphPad Software Inc, La Jolla, CA). For qRT-PCR, the Mann-
Whitney U test was employed to determine if CLDN1 mRNA
expression differed between polyp types. For immunohistochemical
analysis, the chi-squared test was used to determine if the differences in
CLDN1 staining between each polyp type was statistically significant.
Results
Gene expression analysis was performed on SSA/P (n = 5) and MVHP
(n = 5) samples using Affymetrix Human Gene 1.0ST arrays. The SSA/P
samples were obtained from three males and two females (average age 79
years, range 75-82 years). All five polyps were positive for BRAF V600E
mutation. Among the MVHP samples, two polyps were positive for
KRAS mutation in codon 12 or 13 and the remaining three lesions
were wild-type for both BRAF and KRAS. All MVHP samples were
obtained from male subjects (average age 62 years, range 24-79 years).
Analysis of variance of gene expression profiles indicated that 744
genes were differentially expressed between SSA/P and MVHP samples
(adjusted P b .05, fold change ≥ ±2). Furthermore, cluster analysis
(hierarchical analysis and principle component analysis) revealed that
there was no overlap in the transcriptional profiles of these polyp types,
indicating that SSA/P and MVHP have distinct molecular profiles
(Figures 1 andW1). The list of differentially expressed genes is shown in
Table W1. Bioinformatic network analysis of differentially expressed
genes (Ingenuity Pathway Analysis) identified four potential genes as
being upstream regulators, i.e., genes that regulate the expression of
other genes (either upregulate or downregulate) in a manner consistent
with published findings. These upstream regulators include fibrillin-1,
SAM pointed domain containing ETS transcription factor, WNT1
inducible signaling pathway protein 2, and synovial apoptosis inhibitor
1. Each of these genes were predicted to be activated (z-score N2) on the
basis of the direction of the fold change of their downstream targets. The
network representing the regulation of expression of these downstream
targets is shown in Figure W2.
Statistical and bioinformatic analyses of the gene expression data
identified CLDN1 as the most significant differentially expressed gene
(based on adjusted P value) and also as a downstream target ofWNT1
inducible signaling pathway protein 2 (Figure W2). The expression of
CLDN1 was found to be 9.5-fold upregulated in SSA/P samples
when compared with MVHP (P = .003). Accordingly, we undertook
further analysis of this gene in a larger cohort of patient samples to
determine its possible use as a marker of the serrated pathway.qRT-PCR Validation of CLDN1
qRT-PCR was used to investigate CLDN1 expression changes in
SSA/P (n = 18) and MVHP (n = 11) samples with values normalized
to GAPDH. Of the 18 SSA/P samples, 10 were males (average age 76
years, range 66-82 years) and 8 were females (average age 74 years,
Figure 1. Heat map of the differentially expressed genes between
MVHPs and SSA/Ps. The heat map is a representation of
statistically significant (adjusted P b .05) differentially expressed
genes with fold change greater than ± 2 (i.e., 744 genes) between
SSA/Ps (n = 5, BRAFmutant) and MVHPs (n = 5, BRAF wild type).
Hierarchical clustering analysis indicates that SSA/Ps and MVHPs
have distinct gene expression patterns. Green indicates decreased
expression, and red indicates increased expression.
Figure 2. Expression levels of CLDN1 by qRT-PCR. (A) Expression
levels of CLDN1 in SSA/P and MVHPs based on morphology
compared to normal colonic mucosal tissue (mean value of 1). The
median expression levels for CLDN1 was significantly upregulated
in SSA/P (n = 18) when compared to MVHPs (n = 11; P= 0.0001).
(B) Expression levels of CLDN1 in polyps stratified by BRAF
mutation status. CLDN1 expression was significantly (P b .0005)
elevated in polyps positive for the BRAF V600E mutation (n = 23)
when compared to polyps where the mutation was not
detected (n = 6). Abbreviations: BRAF +ve, BRAF V600E
mutant; BRAF −ve, BRAF wild type.
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age 72 years, range 54-78 years) and three were females (average age
54 years, range 49-56 years). Of the SSA/P group, 15 were positive for
BRAF V600E mutation (9 males, average age 74 years; 6 females,
average age 68 years), 1 was positive for KRAS mutation (female, age
75 years), and 2 were wild-type for both the KRAS and BRAF genes
(1 male, age 82 years; 1 female, age 79 years). Of the MVHP group,
six were positive for BRAF V600E mutation (four males; average age
70 years; two females, average age 52 years), three were positive for
KRAS mutation (two males, average age 72 years; one female, age
56 years), and two samples were wild-type for both the KRAS and
BRAF genes (two males, average age 73 years).
A nonparametric approach (Mann-Whitney U test) was employed
to determine if CLDN1 expression was statistically different between
the two polyp groups. When based on morphologic classification
alone, CLDN1 expression was significantly upregulated in SSA/P
(n = 18) when compared to MVHP (n = 11) (P b .0001; Figure 2A).
When these polyps were classified according to BRAF V600E
mutation status, CLDN1 expression was significantly elevated in
BRAF V600E mutant polyps (n = 23) when compared to those with
no mutation (n = 6; P b .0005; Figure 2B).
Immunohistochemical Analysis of CLDN1 Expression
Serrated polyps displaying the morphology of traditional MVHPwere
found to be a heterogeneous group differing in an underlying gene
mutation and also in the mRNA expression of CLDN1 (Figure 2).
Hence, for immunohistochemical analysis, samples (n = 222) were
divided into four groups: SSA/P (characterized by BRAF V600E
mutation, n = 53), MVHP with the BRAF V600E mutation (n = 111),
MVHPwithmutations in codon 12 or 13 of theKRAS gene (n = 23), and
MVHP without mutation in either the BRAF or KRAS gene (n = 35).
Specific patient and polyp characteristics are summarized in Table 1.Representative CLDN1 immunostaining in SSA/P that is either
BRAF V600E mutant or wild-type is shown in Figure 3. Analysis of
these immunohistochemical data showed that the majority of BRAF
V600E mutant SSA/P and MVHP were positive for CLDN1
expression (89% and 81%, respectively). This is in contrast to
MVHP with KRAS mutations where only 35% were found to be
positive for CLDN1 expression (Table 2). Furthermore, in those
MVHP where no mutation was detected in either the KRAS or BRAF
gene, 54% of these were positive for CLDN1 expression. Further
Table 1. Characteristics of the Patient Cohort and Precursor Lesions Used for
Immunohistochemical Analysis of CLDN1 Expression
SSA/P (n = 53) MVHP (n = 169)
Patient cohort
Female (average age) 22 (63 years) 44 (55 years) 8 (65 years) 15 (60 years)
Male (average age) 31 (60 years) 66 (60 years) 15 (62 years) 20 (55 years)
Tumor location
Right colon 29 5 2 2
Left colon 21 77 14 24
Not recorded 3 29 7 9
Mutation status
BRAF mutant 53 111
KRAS mutant 23
No mutation in KRAS or BRAF 35
Abbreviations: BRAF mutant, positive for V600E mutation; KRAS mutant, positive for mutation
in codon 12 or 13.
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expression was significantly associated with BRAF V600E mutation
independently of polyp morphology (Table 3). Negative controls
showed no staining.
Discussion
The concept of hyperplastic polyps being associated with CRC was
raised three decades ago [21] and despite anecdotal case reports
describing CRCs arising in giant hyperplastic polyps or in the
background of multiple hyperplastic polyps, the idea has remained
unchallenged for many years. Since then, a variant of the hyperplastic
polyp, the SSA/P, has been implicated in CRC development and
subsequently accepted as a precursor lesion of predominantly right-
sided CRC with supportive molecular evidence initially reported by
Jass et al. [22]. Detailed characterization of serrated colorectal polyps
subdivided the group of hyperplastic polyps into three categories:
microvesicular, goblet cell rich, and mucin poor, with the micro-
vesicular type being the most prevalent [3]. MVHP and SSA/P have
overlapping morphologic features and distinction between these
polyp types in routine practice may be difficult or impossible,
particularly when the polyps are small or when dealing with biopsies
rather than excised lesions. While SSA/Ps are well known to harbor
the somatic BRAF V600E mutation, this molecular alteration is also
present in a significant proportion of MVHPs [23–26] The presence
of overlapping morphology with SSA/P and molecular alterations,
including the somatic BRAF V600E mutation, raised the possibility
of MVHP to have the ability to progress to more advanced lesions of
the serrated pathway [25,27,2].
In addition to mutations in the BRAF gene, lesions of the serrated
pathway are also characterized by high frequency of MSI and CIMP
[28–30]. Our gene expression analysis has identified 744 genes that
were differentially expressed between MVHP and SSA/P stratified by
BRAF V600E mutation status (adjusted P b .05, fold change ≥ ±2),
providing convincing evidence that these polyp types are most likely
derived from distinct molecular pathways, which is consistent with
other published reports [9,11–13,31]. Several studies have attempted
to identify biomarkers of SSA/P to develop a diagnostic tool to assist
the pathologist to correctly diagnose this polyp type or to expand our
knowledge on biology and underlying molecular events involved in
malignant transformation of these lesions [8–10]. A recently
published study that employed microarray gene expression profiling
with RT-PCR validation on a similar number of MVHPs and SSA/Ps
revealed a strong association of the annexin A10 gene with SSA/P but
not with MVHP making it a potential biomarker of SSA/P [10].Mapping of the most differentially expressed genes in the same study
onto 12 core cancer signaling pathways demonstrated a significant
up-regulation of the CLDN1 gene in SSA/P. Interestingly, both genes
were in the top six of the most differentially expressed genes in our
study (sixth and first, respectively). The fact that CLDN1 was found
to be upregulated in SSA/P in our microarray and not in the previous
work may reflect the stratification of our polyps based on BRAF
mutation status and/or sampling differences as our samples were
obtained with assistance of a laser capture microscope.
Interestingly, the same study demonstrated overexpression of a
trefoil factor family gene, TFF2, in SSA/P and not in MVHP. These
results and our previous observation of overexpression of the TFF1
gene in SSAs indicate the likely involvement of trefoil factor family
genes in serrated pathway neoplasia [9]. A recently published
investigation of immunohistochemical detection of claudin-18
protein (like CLDN1, a component of tight junctions) in serrated
pathway lesions demonstrated a higher expression of this protein in
SSA/P than in hyperplastic polyps or conventional adenomas [8].
In CRC, reports of CLDN1 expression have been contradictory.
For example, overexpression of CLDN1 in adenocarcinoma tissue in
comparison to normal mucosa has been reported [32–34], and more
recently, Bezdekova et al. demonstrated elevated CLDN1 expression
in a cohort of 42 adenomas relative to normal epithelium [35]. In
these studies, cytoplasmic CLDN1 was correlated with disease
progression. However, low CLDN1 tumor expression has also been
observed and a link between metastasis and poor patient prognosis has
been proposed [36–38]. These studies, however, did not report on
molecular characterization of the patient samples tested, and it is
possible that these opposing results can be explained by molecular
features such as BRAF mutation status, MSI, or CIMP. Further
studies on our patient cohort exploring the association between
mutations in the BRAF gene, CLDN1 staining, and patient outcome
are warranted to better understand their use for prognosis.
The dysregulation of CLDN1 expression has also been postulated as
a contributor to colon cancer progression and its up-regulation has been
shown to be associated with the disorganization of tight junction fibrils,
leading to an increase in paracellular permeability [32]. CLDN1
expressing xenograft tumors have been demonstrated to have increased
potential for invasion and metastatic behaviour [39]. In addition, a
positive correlation of CLDN1 expressing CRC cells and their
resistance to anoikis also suggests that CLDN1 may influence tumor
growth and evolution [40]. The role of CLDN1 in the progression of
SSA to cancer has not been investigated and is unknown. However, the
evolution of serrated lesions to CRC appears to be accelerated and faster
than conventional adenomas [18,41] andmay be related to resistance to
anoikis and cellular discohesion. As CLDN1 is associated with both
processes, the serrated polyps showing CLDN1 overexpression may
have increased potential for progression to higher grade lesions through
the serrated pathway neoplasia.
In gastric epithelial cells, CLDN1 has also been described as a
target of the RUNX3 transcription factor [42]. In intestinal tumors,
RUNX3 can potentially inactivate Wnt signaling by interacting with
the β-catenin/TCF4 complex [43]. RUNX3 is one of the core genes
used to classify CIMP high CRC [5] and it is possible that in this
subset of tumors, promoter hypermethylation and subsequent loss of
RUNX3 expression can attenuate β-catenin/TCF signaling leading to
elevated CLDN1 expression. Activation of Wnt signaling in SSA/P is
controversial with evidence in the literature to both support and
oppose this hypothesis. Abnormal β-catenin staining has been shown
Figure 3. Representative immunostaining of CLDN1 protein in SSA/Ps. Two small serrated, non-dysplastic polyps measuring less than
2 mm, located 12 mm apart in rectosigmoid resection specimen are indicated by arrows (A; hematoxylin and eosin stain). The polyp on
the left side (B1; hematoxylin and eosin stain) had a BRAF V600 somatic mutation and demonstrates a strong membranous expression of
CLDN1 on immunohistochemistry (C1; original magnification, ×100). The diminutive polyp on the right side harbored KRAS mutation in
codon 12 and showed no staining for CLDN1 on immunohistochemistry (C2; original magnification, ×100).
Table 2. CLDN1 Immunostaining in SSA/Ps and MVHPs with BRAF and KRAS Gene
Mutation Status
Positive CLDN1 staining Negative CLDN1 staining
SSA/P, BRAF mutant (n = 53) 47 (89%) 6 (11%)
MVHP, BRAF mutant (n = 111) 90 (81%) 21 (19%)
MVHP, KRAS mutant (n = 23) 8 (35%) 15 (65%)
MVHP, no mutation (n = 35) 19 (54%) 16 (48%)
Abbreviations: BRAF mutant, positive for V600E mutation; KRAS mutant, positive for mutation
in codon 12 or 13.
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between nuclear β-catenin staining and BRAF V600E mutation [44–
46]). In contrast, other studies have demonstrated the opposite or
involvement of Wnt signaling only in SSA with neoplastic
progression, implying that Wnt signaling may only be activated late
in the progression of disease for SSA/P [47,48].
Interestingly, CLDN1 is expressed in recently described perineu-
ral-like stromal proliferations in a small fraction of serrated colorectal
polyps including MVHP and SSA/P [49]. These stromal pericryptal
Table 3. Relationship between Positive CLDN1 Immunostaining and BRAF and KRAS Gene
Mutation Status
SSA/P MVHP
BRAF Mutant BRAF Mutant KRASMutant No Mutation
SSA/P, BRAF mutant (n = 53) N/A P = .2246 P b .0001 P = .0006
MVHP, BRAF mutant (n = 111) P = .2246 N/A P b .0001 P = .0021
MVHP, KRAS mutant (n = 23) P b .0001 P b .0001 N/A P = .1484
MVHP, no mutation (n = 53) P = .0006 P = .0021 P = .1485 N/A
Abbreviations: BRAF mutant, positive for V600E mutation; KRAS mutant, positive for mutation
in codon 12 or 13; N/A, statistical comparison not applicable.
462 CLDN1 in serrated colorectal polyps Caruso et al. Translational Oncology Vol. 7, No. 4, 2014proliferations are usually focal and not exceeding 10% of polyp tissue;
however, in rare cases, the spindle cells extensively populate the
lamina propria to become a dominant cell population of the polyp.
Previously reported colorectal lesions such as intestinal perineuriomas
[50] and fibroblastic polyps [51] are most certainly exaggerated
examples of these stromal proliferations and widen the spectrum of
serrated colorectal polyps as the vast majority of these have the
somatic BRAF V600E mutation [16].
This is the first report describing a strong correlation between
CLDN1 expression and BRAF V600E mutation status in serrated
colorectal polyps. CLDN1 mRNA and protein expression was found
to be significantly elevated in SSA/P and MVHP with BRAF V600E
mutation. To date, there is no established direct link between the
oncogenic and activating BRAF V600E mutation and regulation of
CLDN1 expression. Our results support the view of a close
relationship between BRAF mutated MVHP and SSA/P, which
may, in fact, represent a continuous spectrum of the same neoplastic
process [27]. Precise subclassification of MVHP may require the use
of additional ancillary techniques including CLDN1 immunohisto-
chemistry to identify the lesions with different biologic potential for
neoplastic progression to more advanced serrated pathway lesions.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.neo.2014.05.008.
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